
Retired urologist Dr. Samuel Gepi-Attee has shared insights into the challenging medical landscape for men seeking treatment for erectile dysfunction (ED) prior to the revolutionary introduction of sildenafil, commonly known as Viagra. Speaking on the evolution of urological care, Dr. Gepi-Attee highlighted that before the era of oral medications, medical interventions for ED were significantly more invasive and physically demanding for patients than the solutions available today. These historical perspectives offer a rare look into the rigours of sexual medicine before the turn of the millennium.
According to Dr. Gepi-Attee, the primary clinical method for achieving an erection before the 1990s involved direct injections into the penile tissue. These injections typically utilized vasoactive drugs designed to induce blood flow. While effective in producing the desired result, the procedure was often described by patients as highly uncomfortable and technically difficult to self-administer. This era of treatment required a high level of patient commitment and a tolerance for physical discomfort, which often deterred many individuals from seeking help or continuing with the therapy.
The retired urologist, who was himself involved in the clinical development and research surrounding Viagra, noted that the arrival of the blue pill marked a paradigm shift in sexual medicine. The transition from localized, invasive injections to a systemic, oral tablet transformed the patient experience by removing the psychological and physical barriers associated with needles. Dr. Gepi-Attee’s reflections underscore the rapid advancement of medical science in the late 20th century, which moved ED treatment from a niche surgical concern into the mainstream of primary healthcare.
The historical overview provided by Dr. Gepi-Attee serves as a reminder of the significant progress made in urology over the last three decades. By comparing the uncomfortable methods of the past with modern pharmacological successes, he emphasizes the importance of clinical innovation in improving the quality of life for patients. Today, while injections remain a secondary option for those who do not respond to oral medications, they are part of a much broader and more sophisticated suite of treatments that began with the breakthrough research Gepi-Attee helped pioneer.